Durvalumab
Chemical compound
Durvalumab, sold under the brand name Imfinzi, is an anti-cancer medication used for treatment of various types of cancer. It was developed by Medimmune/AstraZeneca.
Nº Q19904005 ★
Common · Knowledge
Durvalumab
Chemical compound
Durvalumab, sold under the brand name Imfinzi, is an anti-cancer medication used for treatment of various types of cancer. It was developed by Medimmune/AstraZeneca.
Last price
—
Floor price
—
7-day median
—
30-day sales
0
30-day range
—
In circulation
0
Price history
median
low – high
sales
No sales in this period
Show table
| Date | median | Low | High | sales |
|---|
Sales history
- Last sale
- —
- 30-day average
- —
- 30-day low
- —
- 30-day high
- —
- Sales 7d
- 0
- Sales 30d
- 0
No sales yet.
Anonymous sales: no buyer or seller shown. Figures count player-to-player sales only.
From Wikipedia
Durvalumab, sold under the brand name Imfinzi, is an anti-cancer medication used for treatment of various types of cancer. It was developed by Medimmune/AstraZeneca. It is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that binds to programmed cell death ligand 1 (PD-L1) on cancer cells and blocks interactions with PD-1 and CD80 (B7.1) on T cells. Durvalumab is an immune checkpoint inhibitor drug. It was approved in for medical use in the United States in May 2017, and in the European Union in September 2018.
Text: Wikipédia, CC BY-SA 4.0. · Image: Fvasconcellos (talk · contribs) (Public domain) ·
Related cards
-
Daratumumab
Chemical compound
Nº Q5222113 ★★
Not listed
-
Nivolumab
Cancer drug, Anti PD-1 monoclonal antibody
Nº Q7041828 ★★
Not listed
-
Dacarbazine
Chemical compound
Nº Q416975 ★
Not listed
-
Ipilimumab
Pharmaceutical drug
Nº Q2459042 ★
Not listed
-
Atezolizumab
Monoclonal anti-PD-L1 antibody
Nº Q20707748 ★
Not listed
-
Imiquimod
Chemical compound
Nº Q423417 ★★
Not listed